{"id":18013,"date":"2022-07-18T17:27:05","date_gmt":"2022-07-18T11:57:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18013"},"modified":"2023-01-02T10:23:24","modified_gmt":"2023-01-02T04:53:24","slug":"wilson-disease-pipeline-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies","title":{"rendered":"Wilson\u2019s Disease Presents Unique Challenges and Demand for Novel Treatment Therapies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d6e99eb8384\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d6e99eb8384\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\/#Wilsons_Disease_Epidemiology\" >Wilson\u2019s Disease Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\/#Wilsons_Disease_Treatment_Market\" >Wilson\u2019s Disease Treatment Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\/#Barriers_and_Challenges_in_Wilsons_Disease_Management\" >Barriers and Challenges in Wilson's Disease Management<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\/#The_Future_Treatment_Landscape_Looks_Promising\" >The Future Treatment Landscape Looks Promising<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\/#Wilsons_Disease_Emerging_Drugs\" >Wilson\u2019s Disease Emerging Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\/#The_Path_Forward\" >The Path Forward<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Wilson\u2019s disease is a rare genetic disorder caused by mutations in the P-type ATPase gene. Wilson\u2019s disease causes defective biliary excretion of copper, leading to its accumulation, particularly in the liver and brain. The <em>ATP7B <\/em>gene is responsible for the transportation of copper from the liver to the intestine to be defecated from the body, failure from which leads to accumulation of copper in the liver, brain, eyes, and other organs, causing life-threatening organ damage. As Wilson\u2019s disease affects various systems in the body, affected individuals tend to develop various signs and symptoms. Some of the Wilson\u2019s disease symptoms include <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-liver-disease-market\">chronic liver disease<\/a> (jaundice, <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/swelling\">swelling<\/a>, abnormal fluid retention, <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/weight-loss\">weight loss<\/a>, <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/nausea-and-vomiting\">nausea<\/a>, and others), and <a href=\"https:\/\/www.delveinsight.com\/blog\/key-companies-in-neurological-disorders-market\">neurologic symptoms<\/a> (tremors, difficulty walking, <a href=\"https:\/\/www.delveinsight.com\/blog\/speech-recognition-technology-in-healthcare\">speech problems<\/a>, impaired thinking ability, <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/depression\">depression<\/a>, <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/anxiety\">anxiety<\/a>, and mood swings), among others. Wilson\u2019s disease progression if left untreated, may cause <a href=\"https:\/\/www.delveinsight.com\/blog\/hepatic-encephalopathy\">liver (hepatic) disease<\/a>, <a href=\"https:\/\/www.delveinsight.com\/blog\/central-nervous-system\">central nervous system dysfunction<\/a>, and death. Early symptoms of Wilson\u2019s disease can lead to proper diagnosis and treatment may prevent serious long-term disability and life-threatening complications. Wilson\u2019s disease treatment is life-long and aimed at lowering copper levels to nontoxic levels, and at preventing the progression of the disease. Also it\u2019s goal is to reverse any symptoms of Wilson\u2019s disease that have appeared because of copper accumulation in the body. Wilson\u2019s disease treatment may be divided into three parts: first, treatment of symptomatic patients; second, maintenance therapy after the copper has been reduced in affected tissues; and third, in asymptomatic Wilson\u2019s disease patients, maintenance therapy may be used from the beginning.<\/p>\n\n\n\n<p>Wilson\u2019s disease condition include a combination of liver disease and neurological and psychiatric problems. Wilson\u2019s disease liver effecting is typically the initial feature in children and young adults. Individuals whose Wilson\u2019s disease diagnosis is done at an older age usually do not have symptoms of liver problems, although they may have very mild liver disease. <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/liver\">Liver disease signs and symptoms<\/a> include yellowing of the skin or whites of the eyes (jaundice), <a href=\"https:\/\/www.delveinsight.com\/report-store\/fatigue-pipeline-insight\">fatigue<\/a>, loss of appetite, and abdominal swelling. Nervous system or <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/mental-disorders\">psychiatric problems<\/a> are often the initial Wilson\u2019s disease features in individuals diagnosed in adulthood and commonly occur in young adults. Symptoms of Wilson\u2019s disease in young adults include clumsiness, tremors, difficulty walking, speech problems, impaired thinking ability, depression, anxiety, and mood swings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wilsons_Disease_Epidemiology\"><\/span><strong>Wilson\u2019s Disease Epidemiology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although damage due to Wilson\u2019s disease begins as early as 6 years of age, symptoms are visible only in adolescence or early adulthood. The epidemiological studies related to Wilson\u2019s disease are less in number and quote a similar prevalence throughout. Some genetic studies indicate a higher prevalence, and the reasons for inconsistency may be due to low rates of diagnosis and misdiagnosis. Wilson\u2019s disease remains difficult to diagnose indication, and Wilson\u2019s disease diagnosis has been historically based on clinical history, genetic testing, and biochemical evaluation; however, low sensitivity and specificity often lead to failure. Additionally, most symptoms are not specific, and varied clinical manifestations make diagnosis challenging.<\/p>\n\n\n\n<p>This autosomal recessive disorder affects approximately <strong>30,000-40,000<\/strong> people worldwide, and around 1 in 90 individuals are carriers of its faulty gene. Assessments as per DelveInsight\u2019s analysts showed that in Japan, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-epidemiology-forecast\">highest Wilson\u2019s disease cases<\/a> were found to be symptomatic which is around <strong>2000 cases<\/strong>; whereas asymptomatic cases were around <strong>300 in 2021.<\/strong> As per our analysis, Wilson\u2019s disease symptoms-specific cases are expected to increase by<strong> 2032.<\/strong><\/p>\n\n\n\n<p>Assessments as per DelveInsight\u2019s analysts showed that there were more than<strong> 500 cases with Hepatic manifestation<\/strong>, around <strong>200 cases with Neurologic manifestation<\/strong>, more than <strong>100 Neuro-hepatic cases <\/strong>and around<strong> 100 cases with other Wilson\u2019s disease manifestations <\/strong>in France in 2021. DelveInsight estimates that the Wilson\u2019s disease prevalence of these manifestations will increase by 2032.<\/p>\n\n\n\n<p>DelveInsight\u2019s analysts also indicated that in 2021, in <strong>Germany <\/strong>there was around <strong>900 cases of WD, <\/strong>which was diagnosed and will increase by 2032.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-epidemiology-forecast\">Wilson\u2019s disease epidemiology segmentation<\/a> constitutes for the prevalent cases of Wilson\u2019s disease, diagnosed cases of Wilson\u2019s disease, prevalent cases of Wilson\u2019s disease based on clinical manifestation, and prevalent cases of Wilson\u2019s disease based on symptoms.&nbsp;<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-epidemiology-forecast\">total prevalent Wilson\u2019s disease patient population<\/a> in the 7MM countries was estimated to be about <strong>37,000 cases<\/strong> in 2021.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wilsons_Disease_Treatment_Market\"><\/span><strong>Wilson\u2019s Disease Treatment Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Wilson\u2019s disease management requires a multidisciplinary approach.<strong> Life-long Wilson\u2019s disease treatment<\/strong> aims to promote the removal of accumulated copper from the body to non-toxic levels and to reverse the signs and symptoms due to the accumulation of copper in the body. The <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/wilson-therapeutics\">conventional drug therapy for Wilson\u2019s disease<\/a> include treating symptomatic individuals, their maintenance after reducing copper, and advising maintenance therapy among asymptomatic individuals. The current Wilson market is valued at around <strong>USD 300 million,<\/strong> and there is just <strong>one late-stage product<\/strong> and <strong>two gene therapies<\/strong> in the pipeline. The several promising novel therapies, including chelators targeting specific cell types and cell- based and gene therapies, may revolutionize the care for Wilson\u2019s disease patients. However, timely clinical diagnosis remains the main challenge, and many unmet needs exist because of possible clinical deterioration in treated patients.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-034bf539-6c57-4f95-8a09-2fdf96cd844a\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.2.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-inmtr15-512-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-inmtr15-516-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-inmtr15-517-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 215.5 71 L 215.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 357.5 71 L 357.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 71 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74.5 71 L 74.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 314.5 L 499 314.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 266.5 L 499 266.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 217.5 L 499 217.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 168.5 L 499 168.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 120.5 L 499 120.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.488866806030273 217)\" x=\"26.488866806030273\" y=\"217\">Market Size in USD Million<\/text><path class=\"highcharts-axis-line\" d=\"M 75 71 L 75 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-inmtr15-516-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><rect aria-label=\"US, 120. Market Size in USD Million (in 2021).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"234\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"36.5\" y=\"58.5\"><\/rect><rect aria-label=\"EU, 100. Market Size in USD Million (in 2021).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"195\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"177.5\" y=\"97.5\"><\/rect><rect aria-label=\"Japan, 70. Market Size in USD Million (in 2021).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"136\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"318.5\" y=\"156.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Wilson&#8217;s Disease Market Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Market Size of Wilson&#8217;s Disease in 2021<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(55,35)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">120<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>120<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(196,74)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">100<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>100<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(340,133)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">70<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>70<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"145.66666666666333\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"287.0000000000033\" y=\"382\">EU<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"428.3333333333333\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"318\">25<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"270\">50<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"221\">75<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"172\">100<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"124\">125<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"75\">150<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Wilson's Disease Market Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Wilson&#8217;s Disease Market Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-inmtr15-517-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Wilson's Disease Market Insights\"},\"subtitle\":{\"text\":\"Market Size of Wilson's Disease in 2021\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Market Size in USD Million (in 2021)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Market Size in USD Million (in 2021)\\\"\\n\\\"US\\\";120\\n\\\"EU\\\";100\\n\\\"Japan\\\";70\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Market Size in USD Million\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Wilson's Disease Market Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-034bf539-6c57-4f95-8a09-2fdf96cd844a\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Among the 7MM, the <strong>United States<\/strong> had the highest <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-market\">Wilson\u2019s disease market share<\/a> in 2021, which accounted for approximately 42% of the total 7MM market. The overall Wilson\u2019s disease market size was around <strong>USD 120 million<\/strong> in 2021. DelveInsight\u2019s analysts estimate that the market will show positive growth by the end of 2032.<\/p>\n\n\n\n<p>In 2021, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-market\">Wilson\u2019s disease market<\/a> for the EU-5 was worth approximately <strong>USD 100 million.<\/strong> The Wilson\u2019s disease market is expected to grow at a noticeable CAGR over the forecast period as per DelveInsight\u2019s estimates. The Japanese Wilson\u2019s disease market was a little under <strong>USD 70 million<\/strong> in 2021. DelveInsight\u2019s forecasts a significant growth in the market size by 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-barriers-and-challenges-in-wilson-s-disease-management\"><span class=\"ez-toc-section\" id=\"Barriers_and_Challenges_in_Wilsons_Disease_Management\"><\/span><strong>Barriers and Challenges in Wilson's Disease Management<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To begin with, researchers are aware of the diagnostic shortfalls. Biomarkers like ceruloplasmin and copper in the liver or 24 h urinary copper analysis are available but are of lesser significance. The absence of biomarkers or Wilson\u2019s disease screening tests in the pediatric population can be another issue leading to no early diagnosis. Next comes challenges in the Wilson\u2019s disease treatment landscape. Currently with no Wilson\u2019s disease cure available, lifelong treatment is necessary to prevent the lethal symptoms. Although current Wilson\u2019s disease treatment with chelating agents and zinc has improved the patients\u2019 disease burden and quality of life. However, <strong>multiple dosages<\/strong> and <strong>severe side effects<\/strong> lead to <strong>poor adherence<\/strong> among the cohort. Outdated guidelines comprising of unbalanced recommendations exacerbate the problem. Furthermore, the lack of research studies for both epidemiology (patient registries) and treatment (including trials) related data adds to the challenges of gathering evidence related to the quality of life among Wilson\u2019s disease patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-future-treatment-landscape-looks-promising\"><span class=\"ez-toc-section\" id=\"The_Future_Treatment_Landscape_Looks_Promising\"><\/span><strong>The Future Treatment Landscape Looks Promising<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-pipeline-insight\">number of Wilson\u2019s drugs<\/a> are available for treatment, including <strong>D-penicillamine, trientine, zinc, tetrathiomolybdate, <\/strong>and <strong>dimercaprol.<\/strong> Once the Wilson\u2019s disease diagnosis has been made, treatment needs to be lifelong. Wilson\u2019s disease treatment ncludes three types of medications. First, those that remove (chelate) copper from the body by urinary excretion, such as penicillamine (Cuprimine) and trientine dihydrochloride (Syprine); second, zinc salts to prevent the gut from absorbing copper from the diet; and third, tetrathiomolybdate which both prevents absorbing copper and binds up toxic copper in the blood making it nontoxic.<\/p>\n\n\n\n<p>Wilson\u2019s disease patients who present symptomatically with mild to moderate liver failure can be effectively treated with a combination of trientine and zinc for 4\u20136 months and then go on maintenance therapy with zinc or trientine alone. A second choice would be penicillamine and zinc, but penicillamine has more side effects than zinc. Patients with severe liver failure may require liver transplantation. Patients who present neurologically can best be treated with tetrathiomolybdate, but it is not commercially available as yet. The second choice is zinc alone. Zinc is rather slow-acting but does not cause the drug catalyzed worsening, so common with trientine and penicillamine. Trientine and penicillamine are poor choices to treat neurologically presenting patients because of the high frequency of neurological worsening, from which many Wilson\u2019s disease patients never recover.<\/p>\n\n\n\n<p>Newborn Wilson\u2019s disease screening tests are being prioritized in some geographies. For this, research and development are underway. As patients are becoming intolerant to chelating agents like penicillamine, the development of newer treatment choices has been emphasized. The recent FDA approval of Cuvrior marks achieving a better and tolerable safety profile. In addition, many other therapies are being assessed in this area \u2013 <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-market\">key Wilson\u2019s disease market players<\/a> include <strong>AstraZeneca<\/strong>, <strong>Vivet Therapeutics, Pfizer<\/strong>, <strong>Ultragenyx Pharmaceutical<\/strong> Inc., and others. AstraZeneca is developing a potential new <strong>once-daily oral medicine<\/strong> designed to be the first targeted de-coppering therapy. Vivet Therapeutics and Ultragenyx Pharmaceutical investigate a replication-deficient recombinant adeno-associated viral vector (<strong>rAAV-based gene therapy vector<\/strong>) and adeno-associated virus serotype 9 (<strong>AAV type 9<\/strong>) based<strong> <\/strong>gene therapies, respectively for Wilson\u2019s disease treatment. The advent of these innovative Wilson\u2019s disease therapies will reinvigorate the treatment landscape and better patient compliance.&nbsp; Payer reimbursement for the costly Wilson\u2019s disease gene therapies would be a challenge, and being in a nascent stage, gene therapies have to prove their cost-effectiveness.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171611\/Key-Companies-Developing-Wilsons-Disease-Therapies.png\" alt=\"Leading Pharma Players in Wilson's Disease Treatment Landscape\" class=\"wp-image-18018\" width=\"484\" height=\"192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171611\/Key-Companies-Developing-Wilsons-Disease-Therapies.png 484w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171611\/Key-Companies-Developing-Wilsons-Disease-Therapies-300x119.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171611\/Key-Companies-Developing-Wilsons-Disease-Therapies-150x60.png 150w\" sizes=\"(max-width: 484px) 100vw, 484px\" \/><figcaption><strong>Leading Pharma Players in Wilson's Disease Treatment Landscape<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wilsons_Disease_Emerging_Drugs\"><\/span><strong>Wilson\u2019s Disease Emerging Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To meet the current demands of the patient pool and to counter the <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/wilson-therapeutics\">unmet needs of the therapeutic Wilson\u2019s disease market<\/a>, drug developers are gradually shifting their attention toward the disease as a possible indication for new targeted therapies. Several companies are working robustly on many new Wilson\u2019s disease therapies, includes ALXN1840 (AstraZeneca), VTX-801 (Vivet Therapeutics\/ Pfizer), and UX701 (Ultragenyx Pharmaceutical). The <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-pipeline-insight\">mid-stage Wilson\u2019s disease pipeline<\/a> is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.<\/p>\n\n\n\n<p><strong>ALXN1840 (AstraZeneca)<\/strong> is a potential new once-daily oral medicine in development for Wilson\u2019s disease. It is designed to be the first targeted de-coppering therapy that selectively and tightly binds to, and removes, copper from the body\u2019s tissues and blood. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-pipeline-insight\">Wilson\u2019s disease drug<\/a> is currently in Phase III trial (FOCUS), with positive high-level results from the trial. ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilization from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. The drug has been granted Orphan Drug Designation in the US and EU for Wilson\u2019s disease treatment. The trial enrolled 214 patients, including treatment-na\u00efve participants and those who have been on SoC therapy for an average of 10 or more years. ALXN1840, a potential new oral medicine, demonstrated approximately three times greater copper mobilization than SoC.<\/p>\n\n\n\n<p><strong>UX701 (Ultragenyx Pharmaceutical)<\/strong> is an investigational AAV type 9 gene therapy designed to deliver a stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion. The <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/wilson-therapeutics\">Wilson\u2019s disease therapy<\/a> has been shown in preclinical studies to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease. UX701 is currently in Phase I\/II\/III. The company has also received FDA IND clearance, which allows for advancing this new gene therapy in the clinic and hopes for a new treatment for patients with WD. UX701 has the potential to directly address the underlying basis of disease by restoring the normal transport and excretion of copper. The therapy was granted Orphan Drug Designation in the United States.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-path-forward\"><span class=\"ez-toc-section\" id=\"The_Path_Forward\"><\/span><strong>The Path Forward<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Timely commencement of Wilson\u2019s disease treatment achieved through early diagnosis is the key to managing the disease effectively. Clarity among recommendations gathered through thorough clinical evidence can help smoothen the management process. As more key pharma companies develop <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-pipeline-insight\">potential Wilson\u2019s disease drug candidates<\/a> and new players begin to focus on this indication, patients will eventually have plenty to choose from. With the launch of these promising agents, <a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-market\">Wilson\u2019s disease market<\/a> is expected to grow with a significant CAGR. However, the high price of these therapies can be troublesome and must be kept in check.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/wilson-disease-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-1024x194.png\" alt=\"Wilson's Disease Market\n\" class=\"wp-image-18019\" width=\"1024\" height=\"194\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18171741\/Wilsons-Disease.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Wilson\u2019s disease is a rare genetic disorder caused by mutations in the P-type ATPase gene. Wilson\u2019s disease causes defective biliary excretion of copper, leading to its accumulation, particularly in the liver and brain. The ATP7B gene is responsible for the transportation of copper from the liver to the intestine to be defecated from the body, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":18023,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19520,19523,19522,19548,19521,19524,19546,19545],"industry":[17225],"therapeutic_areas":[17235,17238,17234],"class_list":["post-18013","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-wilsons-disease","tag-wilsons-disease-drugs","tag-wilsons-disease-epidemiology","tag-wilsons-disease-management","tag-wilsons-disease-market","tag-wilsons-disease-pipeline","tag-wilsons-disease-therapies","tag-wilsons-disease-treatment","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Wilson\u2019s Disease Treatment Market To Rise Exponentially in Future<\/title>\n<meta name=\"description\" content=\"With the launch of many promising agents, Wilson\u2019s disease treatment market is expected to grow tremendously with a significant CAGR.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wilson\u2019s Disease Treatment Market To Rise Exponentially in Future\" \/>\n<meta property=\"og:description\" content=\"With the launch of many promising agents, Wilson\u2019s disease treatment market is expected to grow tremendously with a significant CAGR.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-18T11:57:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-02T04:53:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18172343\/Wilsons-Disease-Image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wilson\u2019s Disease Treatment Market To Rise Exponentially in Future","description":"With the launch of many promising agents, Wilson\u2019s disease treatment market is expected to grow tremendously with a significant CAGR.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies","og_locale":"en_US","og_type":"article","og_title":"Wilson\u2019s Disease Treatment Market To Rise Exponentially in Future","og_description":"With the launch of many promising agents, Wilson\u2019s disease treatment market is expected to grow tremendously with a significant CAGR.","og_url":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-07-18T11:57:05+00:00","article_modified_time":"2023-01-02T04:53:24+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18172343\/Wilsons-Disease-Image.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies","url":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies","name":"Wilson\u2019s Disease Treatment Market To Rise Exponentially in Future","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18172343\/Wilsons-Disease-Image.png","datePublished":"2022-07-18T11:57:05+00:00","dateModified":"2023-01-02T04:53:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"With the launch of many promising agents, Wilson\u2019s disease treatment market is expected to grow tremendously with a significant CAGR.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/wilson-disease-pipeline-therapies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18172343\/Wilsons-Disease-Image.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18172343\/Wilsons-Disease-Image.png","width":772,"height":482,"caption":"Wilson's Disease Image"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/18172343\/Wilsons-Disease-Image-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease management<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wilson&#039;s disease treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Wilson&#039;s disease<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease drugs<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease management<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease market<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease therapies<\/span>","<span class=\"advgb-post-tax-term\">Wilson&#039;s disease treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jul 18, 2022","modified":"Updated on Jan 2, 2023"},"absolute_dates_time":{"created":"Posted on Jul 18, 2022 5:27 pm","modified":"Updated on Jan 2, 2023 10:23 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18013"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18023"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18013"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18013"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}